ORLISTAT

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ORLISTAT
Generic name
ORLISTAT
Manufacturer
H2-Pharma LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
f81dfaeb-46d5-47ce-9ef6-19259f5ac61c
SPL ID
b29974a6-e39c-4501-a26d-47d1cc0616d0
Version
8
Effective date
2026-09-30
Source export date
2026-11-13
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:55:27
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Loss of Effect of Certain Medications and Dietary Supplements with Coadministration of ORLISTAT: Serious outcomes due to the loss of effect of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene have been reported with coadministration of ORLISTAT. ( 5.1 ) Liver Injury: Severe liver injury with hepatocellular necrosis or acute hepatic failure have been reported in patients treated with ORLISTAT, some cases resulted in liver transplant or death. Instruct patients to report any symptoms of hepatic dysfunction, immediately discontinue if symptoms occur and obtain liver function tests. ( 5.2 ) Oxalate Nephrolithiasis and Oxalate Nephropathy with Renal Failure: Monitor renal function in patients at increased risk for oxalate nephropathy. Discontinue ORLISTAT in patients who develop oxalate nephropathy. ( 5.3 ) Acute Gallbladder Disease: Has occurred in clinical trials and in postmarketing. If suspected, gallbladder studies and appropriate clinical follow-up are indicated. ( 5.4 ) Gastrointestinal Events: May increase when ORLISTAT is taken with a diet high in fat (>30% total daily calories from fat). Advise patients to adhere to dietary guidelines and distribute the daily intake of fat over three main meals. ( 5.5 ) 5.1 Loss of Effect of Certain Medications and Dietary Supplements with Coadministration of ORLISTAT Serious outcomes due to the loss of effect of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene have been reported with coadministration of ORLISTAT. Do not coadminister ORLISTAT simultaneously with cyclosporine or levothyroxine [see Drug Interactions ( 7 )]. Administer cyclosporine 3 hours after the administration of ORLISTAT. Administer levothyroxine and ORLISTAT at least 4 hours apart. Administer a multivitamin supplement at least 2 hours before or 2 hours after the administration of ORLISTAT, or at bedtime. Monitor the effectiveness of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene, as clinically indicated [see Drug Interactions ( 7 ) and Clinical Pharmacology ( 12.3 )]. 5.2 Liver Injury There have been rare postmarketing reports of severe liver injury with hepatocellular necrosis or acute hepatic failure in patients treated with ORLISTAT, with some of these cases resulting in liver transplant or death [see Adverse Reactions ( 6.2 )]. Instruct patients to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain) while taking ORLISTAT. When these symptoms occur, immediately discontinue ORLISTAT and other suspected medications and obtain liver function tests, including ALT and AST levels. 5.3 Oxalate Nephrolithiasis and Oxalate Nephropathy with Renal Failure ORLISTAT may increase levels of urinary oxalate. Cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported [see Adverse Reactions ( 6.2 )]. Monitor renal function when prescribing ORLISTAT to patients at increased risk for oxalate nephropathy, including patients with renal impairment and in those with a history of hyperoxaluria or calcium oxalate nephrolithiasis. Discontinue ORLISTAT in patients who develop oxalate nephropathy. 5.4 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis, have been reported in clinical trials and during the postmarketing experience with ORLISTAT. In a 4-year clinical trial of ORLISTAT, cholelithiasis was reported in 2.9% (47/1649) of ORLISTAT-treated patients versus 1.8% (30/1655) of placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. 5.5 Gastrointestinal Events Gastrointestinal events may increase when ORLISTAT is taken with a diet high in fat (>30% total daily calories from fat) [see Adverse Reactions ( 6.1 )]. Advise patients receiving ORLISTAT to adhere to dietary guidelines [see Dosage and Administration ( 2 )]. The daily intake of fat should be distributed over three main meals. If ORLISTAT is taken with any one meal very high in fat, the possibility of gastrointestinal effects increases.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 4 matching rows.

adverse reactions

6 ADVERSE REACTIONS Most common treatment emergent adverse reactions (≥5% and at least twice that of placebo) include oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact the Safety Call Center at 1-888-236-5445 or FDA at 1‑800‑FDA‑1088 (1-800-332-1088) or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients. Most Commonly Observed Adverse Reactions during 1 Year of Treatment ORLISTAT was evaluated for safety in adults with obesity or overweight with at least one comorbid condition in seven multicenter, double-blind, placebo-controlled clinical trials of 1- to 2-years duration, and in a 4-year trial. The seven trials included 1,466 patients treated with placebo, 1,913 patients treated with ORLISTAT 120 mg orally three times a day, and 809 patients treated with unapproved dosages of ORLISTAT. Age of the patients ranged from 17 to 78 years; 80% were female, 91% White, 6% Black or African American, 2% were of Hispanic or Latino ethnicity, and 1% of other races. Six of the trials enrolled patients without type 2 diabetes mellitus (Trials 1-6) and one of the trials enrolled a population of patients with type 2 diabetes mellitus (Trial 7). The 4-year trial (Trial 8) included 3,304 patients, age range 30-58 years; 55% were female; 99% were White and 1% other races. This trial included a subset of patients with abnormal glucose at baseline [see Clinical Studies ( 14.1 )] . In placebo-controlled clinical trials, 9% of patients treated with ORLISTAT discontinued treatment due to adverse reactions, compared with 5% of placebo-treated patients. The most common adverse reactions that led to discontinuation of ORLISTAT treatment were gastrointestinal in nature. Gastrointestinal symptoms, as shown in Table 1, were the most commonly observed adverse reactions associated with the use of ORLISTAT in the first year of seven placebo-controlled clinical trials. In general, the first occurrence of these events was within 3 months of starting therapy. Table 1 Adverse Reactions (5% and an incidence at least twice that of placebo) in ORLISTAT-Treated Adults with Obesity or Overweight for Chronic Weight Management During 1 Year of Treatment Adverse Event Placebo % Patients (N=1,466) ORLISTAT % Patients (N=1,913) Oily Spotting a 1 27 Flatus with Discharge 1 24 Fecal Urgency 7 22 Fatty/Oily Stool a 3 20 Oily Evacuation a 1 12 Increased Defecation 4 11 Fecal Incontinence 1 8 a Oily discharge may be clear or have a coloration such as orange or brown. Table 2 lists other adverse reactions from the seven placebo-controlled clinical trials that occurred at a frequency of ≥3% among patients treated with ORLISTAT and with an incidence that was greater than placebo during year 1. Table 2 Adverse Reactions (incidence ≥3% and greater than placebo) from Seven Placebo-Controlled Clinical Trials During 1 Year of Treatment Adverse Event Placebo % Patients (N=1,466) ORLISTAT % Patients (N=1,913) Influenza 36 40 Upper Respiratory Infection 33 38 Headache 28 31 Abdominal Pain/Discomfort 21 26 Back Pain 12 14 Menstrual Irregularity 8 10 Lower Respiratory Infection 7 8 Nausea 7 8 Urinary Tract Infection 7 8 Fatigue 6 7 Arthritis 5 5 Dizziness 5 5 Anxiety 3 5 Infectious Diarrhea 4 5 Rectal Pain/Discomfort 4 5 Vaginitis 4 4 Rash 4 4 Vomiting 4 4 Otitis 3 4 Sleep Disorders 3 4 Myalgia 3 4 Tooth Disorder 3 4 Gingival Disorder 3 4 Other Adverse Reactions Low Vitamin Levels Table 3 illustrates the percentage of adult patients on ORLISTAT and placebo who developed a low blood vitamin level on two or more consecutive visits in studies up to 2 years in which patients were not previously receiving vitamin supplementation. Table 3 Incidence of Low Blood Vitamin Values on Two or More Consecutive Visits (Adult Patients with Normal Nonsupplemented Baseline Values) Placebo % Patients ORLISTAT % Patients Vitamin D 7 12 Beta-carotene 2 6 Vitamin E 1 6 Vitamin A 1 2 Adverse Reactions in Patients with Type 2 Diabetes Mellitus Hypoglycemia and abdominal distension were also reported in clinical trials in patients with type 2 diabetes mellitus and overweight or obesity. Adverse Reactions in Pediatric Patients Aged 12 Years and Older with Obesity In clinical trials with ORLISTAT in pediatric patients aged 12 years and older with obesity, adverse reactions were similar to those reported in adults [see Clinical Studies ( 14.2 )]. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ORLISTAT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to ORLISTAT exposure. Immune System: Rare cases of hypersensitivity. Signs and symptoms have included pruritus, rash, urticaria, angioedema, bronchospasm and anaphylaxis. Very rare cases of bullous eruption. Gastrointestinal: Pancreatitis; lower gastrointestinal bleeding. Hepatobiliary : Hepatitis that may be serious, and hepatic failure, with some of these cases resulting in liver transplant or death [see Warnings and Precautions ( 5.2 )] ; cholelithiasis [see Warnings and Precautions ( 5.4 )] ; increases in transaminases and alkaline phosphatase. Skin and Subcutaneous Tissue : Leukocytoclastic vasculitis. Clinical signs include palpable purpura, maculopapular lesions, or bullous eruption. Renal and Urinary: Acute oxalate nephropathy and hyperoxaluria in patients with or at risk for renal disease.

adverse reactions table

<table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph"> <content styleCode="bold">Adverse</content> <content styleCode="bold">Event</content> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph"> <content styleCode="bold">Placebo</content> </paragraph> <paragraph styleCode="TableParagraph"> <content styleCode="bold">%</content> <content styleCode="bold">Patients (N=1,466)</content> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph"> <content styleCode="bold">ORLISTAT</content> </paragraph> <paragraph styleCode="TableParagraph"> <content styleCode="bold">%</content> <content styleCode="bold">Patients (N=1,913)</content> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Oily Spotting<sup>a</sup> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">1</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">27</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Flatus with Discharge</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">1</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">24</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Fecal Urgency</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">7</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">22</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Fatty/Oily Stool<sup>a</sup> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">3</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">20</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Oily Evacuation<sup>a</sup> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">1</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">12</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Increased Defecation</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">4</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">11</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Fecal Incontinence</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">1</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">8</paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr> <td valign="top"> <paragraph> <content styleCode="bold">Adverse</content> <content styleCode="bold">Event</content> </paragraph> </td> <td valign="top"> <paragraph> <content styleCode="bold">Placebo</content> </paragraph> <paragraph> <content styleCode="bold">%</content> <content styleCode="bold">Patients (N=1,466)</content> </paragraph> </td> <td valign="top"> <paragraph> <content styleCode="bold">ORLISTAT</content> </paragraph> <paragraph> <content styleCode="bold">%</content> <content styleCode="bold">Patients (N=1,913)</content> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>In&#xFB02;uenza</paragraph> </td> <td valign="top"> <paragraph>36</paragraph> </td> <td valign="top"> <paragraph>40</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Upper Respiratory Infection</paragraph> </td> <td valign="top"> <paragraph>33</paragraph> </td> <td valign="top"> <paragraph>38</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Headache</paragraph> </td> <td valign="top"> <paragraph>28</paragraph> </td> <td valign="top"> <paragraph>31</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Abdominal Pain/Discomfort</paragraph> </td> <td valign="top"> <paragraph>21</paragraph> </td> <td valign="top"> <paragraph>26</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Back Pain</paragraph> </td> <td valign="top"> <paragraph>12</paragraph> </td> <td valign="top"> <paragraph>14</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Menstrual Irregularity</paragraph> </td> <td valign="top"> <paragraph>8</paragraph> </td> <td valign="top"> <paragraph>10</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Lower Respiratory Infection</paragraph> </td> <td valign="top"> <paragraph>7</paragraph> </td> <td valign="top"> <paragraph>8</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Nausea</paragraph> </td> <td valign="top"> <paragraph>7</paragraph> </td> <td valign="top"> <paragraph>8</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Urinary Tract Infection</paragraph> </td> <td valign="top"> <paragraph>7</paragraph> </td> <td valign="top"> <paragraph>8</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Fatigue</paragraph> </td> <td valign="top"> <paragraph>6</paragraph> </td> <td valign="top"> <paragraph>7</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Arthritis</paragraph> </td> <td valign="top"> <paragraph>5</paragraph> </td> <td valign="top"> <paragraph>5</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Dizziness</paragraph> </td> <td valign="top"> <paragraph>5</paragraph> </td> <td valign="top"> <paragraph>5</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Anxiety</paragraph> </td> <td valign="top"> <paragraph>3</paragraph> </td> <td valign="top"> <paragraph>5</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Infectious Diarrhea</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> <td valign="top"> <paragraph>5</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Rectal Pain/Discomfort</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> <td valign="top"> <paragraph>5</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Vaginitis</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Rash</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Vomiting</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Otitis</paragraph> </td> <td valign="top"> <paragraph>3</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Sleep Disorders</paragraph> </td> <td valign="top"> <paragraph>3</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Myalgia</paragraph> </td> <td valign="top"> <paragraph>3</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Tooth Disorder</paragraph> </td> <td valign="top"> <paragraph>3</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Gingival Disorder</paragraph> </td> <td valign="top"> <paragraph>3</paragraph> </td> <td valign="top"> <paragraph>4</paragraph> </td> </tr> </tbody> </table>

adverse reactions table

<table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr> <td valign="top"/> <td valign="top"> <paragraph styleCode="First TableParagraph"> <content styleCode="bold">Placebo</content> </paragraph> <paragraph styleCode="TableParagraph"> <content styleCode="bold">% Patients</content> </paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph"> <content styleCode="bold">ORLISTAT</content> </paragraph> <paragraph styleCode="TableParagraph"> <content styleCode="bold">% Patients</content> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Vitamin D</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">7</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">12</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Beta-carotene</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">2</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">6</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Vitamin E</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">1</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">6</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph styleCode="First TableParagraph">Vitamin A</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">1</paragraph> </td> <td valign="top"> <paragraph styleCode="First TableParagraph">2</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.